The COVID-19 Pandemic and the Escalation of Rhino-Orbital-Cerebral Mucormycosis: A Retrospective Review
DOI:
https://doi.org/10.52206/jsmc.2025.15.3.1215Abstract
Background: The COVID-19 pandemic has contributed to a surge in secondary opportunistic infections, notably rhino-orbital-cerebral mucormycosis (ROCM) a rare but aggressive fungal infection. Its emergence, particularly in individuals with immunosuppressive conditions such as uncontrolled diabetes or corticosteroid exposure, poses serious clinical challenges.
Objective: This study aimed to characterize the demographic and clinical profiles of post-COVID-19 patients with ROCM, evaluate medical and surgical interventions, identify key prognostic factors such as diabetes, steroid use, and intracranial involvement.
Methodology: A retrospective analysis was conducted on 68 patients diagnosed with ROCM at Saidu Group of Teaching Hospitals, Swat, Pakistan, between January 2021 and August 2024. Data on demographics, comorbidities, COVID-19 history, clinical presentation, disease extent, surgical interventions, and outcomes were collected. Statistical tests were applied to identify predictors of mortality.
Results: Of the 68 patients, 61% were male, aged 35–73 years. Diabetes mellitus was present in 91.17%, and 88.3% had a recent history of COVID-19. Hemifacial pain, orbital complications, and vision loss were common. All patients underwent surgical debridement 88.23% via modified endoscopic Denker’s approach. The mortality rate was 32.3%, while 62% achieved disease-free status. Intracranial extension (p<0.001) and uncontrolled diabetes (p=0.016) were significantly associated with mortality. Steroid use showed a non-significant trend (p=0.12).
Conclusion: COVID-19-associated ROCM predominantly affected diabetic males and presented with aggressive, multisystem involvement. Despite surgical and antifungal management, mortality remained high. Early diagnosis, strict glycemic control, and multidisciplinary care are critical for improving outcomes. Further research should focus on rapid diagnostics and optimized treatment strategies to mitigate the burden of this life-threatening condition.
Keywords: COVID-19, Mucormycosis, Rhino-Orbital-Cerebral Infections, Type 2 Diabetes Mellitus.
References
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
Gupta DP, Gupta S, Shah CK, Sreevidya SR. Clinical Study of Surge of Mucormycosis in COVID-19 Pandemic: A Tertiary Care Center Study. Indian J Otolaryngol Head Neck Surg. 2022;74(Suppl 2):3455-3462. https://doi.org/10.1007/s12070-021-02784-6
Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux JP, et al. The emergence of COVID-19 associated mucormycosis: A review of cases from 18 countries. Lancet Microbe. 2022;3(7):e543-e552. https://doi.org/10.1016/S2666-5247(21)00237-8
Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12(9):e10726. https://doi.org/10.7759/cureus.10726
Pippal SK, Kumar D, Ukawat L. Management Challenge of Rhino-Orbito-Cerebral Mucormycosis in Covid 19 Era: A Prospective Observational Study. Indian J Otolaryngol Head Neck Surg. 2022;74 (Suppl 2):3485-3491. https://doi.org/10.1007/s12070-021-02947-5
Saini S, Singh SP, Singh VK, Kumar S, Singh S, Rajak SD. COVID-19-Associated Rhino-orbital mucormycosis: Presentation and outcome. Saudi J Ophthalmol. 2023;37(1):72-75. https://doi.org/10.4103/sjopt.sjopt_154_21
Fouad YA, Abdelaziz TT, Askoura A, Saleh MI, Mahmoud MS, Ashour DM, et al. Spike in Rhino-Orbital-Cerebral Mucormycosis Cases Presenting to a Tertiary Care Center During the COVID-19 Pandemic. Front Med. 2021;8:645270 https://doi.org/10.3389/fmed.2021.645270
John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: The perfect storm for mucormycosis. J Fungi. 2021;7(4):298. https://doi.org/10.3390/jof7040298
Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146. https://doi.org/10.1016/j.dsx.2021.05.019
Ravani SA, Agrawal GA, Leuva PA, Modi PH, Amin KD. Rise of the phoenix: Mucormycosis in COVID-19 times. Indian J Ophthalmol. 2021;69(6):1563-1568. https://doi.org/10.4103/ijo.IJO_310_21
Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-e421. https://doi.org/10.1016/S1473-3099(19)30312-3
Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis. 2021;27(9): 2349-2359. https://doi.org/10.3201/eid2709.210934
Ramaswami A, Sahu AK, Kumar A, Nair A. COVID-19-associated mucormycosis: A systematic review and meta-analysis of 958 cases. Mycoses. 2021;64(10):1202-1210. https://doi.org/10.1016/j.cmi.2023.03.008
Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: An update. J Fungi. 2020;6(4):265. https://doi.org/10.3390/jof6040265
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 The authors retain the copyrights. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on their website), as it can lead to productive exchanges, as well as greater citation of published work.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
